Imipenem and cilastatin concentrations in serum were determined by using reverse-phase high-pressure liquid chromatography. Serum samples were stabilized with 0.5 M morpholineethanesulfonic acid buffer (pH 6.0) and subjected to ultrafiltration before chromatography. The elution solvent consisted of water or potassium phosphate buffered to pH 2.5 and methanol. The imipenem and cilastatin peaks were detected at 300 and 220 nm, respectively. Recovery from serum was 99% for both imipenem and cilastatin, and the limits of detectability for the two compounds were 0.3 and 0.5 ,ug/ml, respectively. The assay may be readily applied to pharmacokinetic analysis of imipenem and cilastatin biodisposition in patients.
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Imipenem, a stable derivative of thienamycin, is a new carbapenem antibiotic derived from Streptomyces cattleya (3) . It is an antibiotic with an unusually broad spectrum of antimicrobial activity that includes isolates resistant to most other agents (1, 7, 8) . This breadth of antimicrobial activity is probably due to resistance to hydrolysis by bacteriallactamases (6) .
The pharmacokinetics of imipenem in normal volunteers have been evaluated by using microbiological assay techniques (5). These studies have revealed a highly variable urinary recovery, despite rapid renal clearance of the drug. This probably results from the metabolism of imipenem by the dipeptidase dehydropeptidase I, located on the brush border of the proximal tubule (2) . For clinical purposes, imipenem has been combined with an inhibitor of this enzyme to enhance urinary recovery of the drug (4) .
We report here a rapid and sensitive high-pressure liquid chromatographic (HPLC) procedure for the determination of both imipenem and the dehydropeptidase inhibitor, cilastatin, in serum. The methodology may be easily applied to pharmacokinetic analyses of imipenem and cilastatin biodisposition in patients.
MATERIALS AND METHODS Reagents. Imipenem and the dehydropeptidase inhibitor cilastatin ( Fig. 1) The mobile phase for imipenem consisted of 93% water and 7% methanol; that for cilastatin was 76% 0.10 M potassium phosphate (pH 2.5) and 24% methanol. Both mobile phases were run at 1 ml/min. Peak detection was accomplished with a UV 50 variable wavelength detector set at 300 nm for imipenem and 220 nm for cilastatin (Fig. 2) . The chromatograms were printed at an attenuation of 16 and a chart speed of 0.2 cm/min.
In the case of the imipenem method, the relatively high ionic strength of the specimens themselves kept the column conditioned. Therefore, the first injection of the day ought to be a salt blank (e.g., 50% pH 6, 0.5 M MES-50% pH 7, 0.15 M sodium phosphate). In the application of the cilastatin method to patient sera, it was occasionally necessary to alter the methanol concentration or the ionic strength of the phosphate buffer in the mobile phase to separate cilastatin from other components. Sample preparation. Blood was permitted to clot on ice, and serum was separated by centrifugation. The serum was diluted with an equal volume of 0.5 M MES buffer (pH 6.0). The stabilized sample was stored at -70°C before analysis. To increase stability at -20°C, ethylene glycol may be added (see below), but this can result in the appearance of additional peaks in the chromatograms for both agents, depending on the type and source of ethylene glycol used. It was, therefore, avoided in the present study.
Before analysis, a 0.7-mI portion of the diluted specimen was subjected to ultrafiltration, using an Amicon Centifree micropartition system in a clinical tabletop centrifuge with an angle head rotor. The YMT membrane in the ultrafiltration system retains >99.9% of serum proteins but <5% of Lthyroxine. Since the protein binding of both imipenem and cilastatin is .25% (data on file at Merck Research Laboratories, West Point, Pa.) and recovery of both agents from spiked serum samples exceeds 90% (see below), the drug concentrations in the filtrate are considered to represent total drug. Centrifugation was performed for 30 min at 1,000 to 2,000 x g. If the sample obtained was plasma or contained ethylene glycol, a longer period of centrifugation was required and less filtrate was obtained. Filtrates were brought ,., to room temperature and vortexed immediately before injection. Imipenem in the filtrate was stable on ice for at least 6 h. The filtrate could be stored at -20°C for later determination of cilastatin.
Standards. A 1-mg/ml stock solution of imipenem was prepared in 0.25 morpholinepropanesulfonic acid buffer (pH 6.8). The 1-mg/ml stock solution of cilastatin was prepared in 0.2% sodium carbonate. Standards for HPLC determination were prepared in 1:1 mixtures of serum and 0.5 M MES (pH 6.0) and were frozen at -70°C.
Calculations. No internal standard was needed because of the direct method of sample preparation. Good coefficients of variation supported the use of an external standard. Peak areas were measured in both methods. All concepltrations are expressed per milliliter of original undiluted serum sample.
RESULTS AND D)ISCUSSION
Chromatography is shown in Fig. 3 and 4 . The analysis for both assays was linear to 100 pLg/ml. Duplicate stabilized serum samples at 0.5, 2, 5, 20, 40, 75, and 100 jig/ml yielded correlation coefficients of 0.99992 and 0.99958 between peak area and serum concentration for imipenem and cilastatin, respectively. The mean absolute deviation from a straight line was 0.31 and 1.3 p.g/ml, and the limit of sensitivity was 0.3 and 0.5 jig/ml for imipenem and cilastatin, respectively.
The recovery for both drugs from serum was 99%, and the recovery fro,m plasma was 94%. It is recommended that serum be collected' instead of plasma because the serum ultrafiltration time is shorter, more filtrate is obtained, and the recovery of both drugs is greater. The same-day coefficient of variation for imipenem in stabilized serum at 20 ,ug/ml (n = 16) was 1.8 and at 2 ,ug/ml (n = 18) was 6.2. The between-day coefficient of variation at 20 gg/ml (n = 15) was 3.2.
For cilastatin, the same-day coefficient of variation at 20 p.g/ml (n = 20) was 3.4 and at 2 ,ug/ml (n = 15) was 5.4. The between-day coefficient of variation at 20 ,g/ml (n = 10) was 3.9.
Imipenem in buffered serum was completely stable at -70°C over the 90-day study period. However, during the same period at -20 and 4°C, peak areas decreased more than 90% (Fig. 5) Studies were conducted to determine whether other compounds interfered with the methods described above. Neither the compounds tested (Table 2 ) nor unknown peaks in pooled sera eluted at the same time as either imipenem or cilastatin. In our experience with the chromatography of patient sera for imipenem, no peaks later than 24 min were large enough to interfere with later chromatograms. However, in the method for cilastatin, late-eluting peaks, including caffeine, occasionally appeared in subsequent chromatograms. Therefore, we included a wash at 50% methanol and 50% pH 2.5 potassium phosphate at the end of each sample injection. We have presented a rapid and sensitive HPLC assay for imipenem and the renal dehydropeptidase inhibitor cilastatin. It requires less than 0.5 ml of serum to perform both analyses. The pharmacokinetics of imipenem have been reported previously by Norrby et al. (5) . Their calculated pharmacokinetic parameters, determined by a microbiological assay on samples from normal volunteers, were indistinguishable from those obtained by studying imipenem biodisposition in a group of patients receiving the drug for acute pulmonary exacerbations of cystic fibrosis (manuscript in preparation). Nevertheless, methodology for the determination of cilastatin in biological fluids has not been reported.
Our procedure should permit the further pharmacokinetic evaluation of this fixed-combination agent.
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